NFE2L2 and pachyonychia congenita: Several unexplored strategies, i.e. targeting the β-TrCP-Nrf2 binding and HRD1-Nrf2 binding or developing Nrf2 PROTACs may be investigated for specific Nrf2-targeted agents for PC prevention and therapy.